Table 3.
Characteristics of included trials. ASA, American Society of Anesthesiologists; roc, rocuronium; sug, sugammadex
| Trial | Number of patients | Age of population | Gender | ASA physical status | Weight | Treatment arms (n treated) | Outcome measures |
|---|---|---|---|---|---|---|---|
| Placebo-controlled trials | |||||||
| de Boer and colleagues10 | 45 | Mean 42 (sd 15) yr (43 patients) | 22/43 (51%) males | ASA I 32/43 (74%) | Overall weight, mean 76 (sd 18) kg | 1. Roc 1.2 mg kg−1+sug 16 mg kg−1 (n=7) | Time to TOF ratio=0.9 from administration of sugammadex or placebo (5 min after rocuronium) |
| ASA II 11/43 (26%) | 2. Roc 1.2 mg kg−1+placebo (n=4) | ||||||
| Puhringer and colleagues11 | 176 | Mean 50 (sd 16) yr | 93/173 (54%) males | ASA I 66/173 (38%) | Overall weight, mean 77 (sd 15) kg | 1. Roc 1 mg kg−1+sug 16 mg kg−1 (n=10) | Time to TOF ratio=0.7, 0.9 from administration of sugammadex or placebo (3 min after rocuronium) |
| ASA II 88/173 (51%) | 2. Roc 1 mg kg−1+placebo (n=5) | ||||||
| ASA III 19/173 (11%) | 3. Roc 1.2 mg kg−1+sug 16 mg kg−1 (n=11) | ||||||
| 4. Roc 1.2 mg kg−1+placebo (n=5) | |||||||
| Active-control trial | |||||||
| Lee and colleagues12 | 115 randomized | Mean 42 yr (range 18–65 yr) | 42% males (46/110 calculated) | ASA I 70/110 (64%) calculated | Not reported. Mean BMI 25 (sd 3) kg/m2 | 1. Roc 1.2 mg kg−1+sug 16 mg kg−1 (n=55) | Time to T1/T0=0.1 and 0.9 from administration of NMBA |
| ASA II 40/110 (36%) calculated | 2. Succinylcholine 1 mg kg−1 (n=55) | Time from administration of sugammadex (3 min after rocuronium) to TOF ratio=0.7, 0.8, 0.9 (sugammadex group only) | |||||
| Clinical signs of recovery | |||||||